Cerevance Media Center
Current News
February 1, 2021
Cerevance Appoints Carrie Ann Cook as Chief Business Officer
Cerevance, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer
February 1, 2021
Cerevance Appoints Naidong Ye, Ph.D. as Vice President and Head of Chemistry, Manufacturing and Controls
Cerevance today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
December 8, 2020
Cerevance Appoints David Lubner to Board of Directors
Cerevance today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors.
November 16, 2020
Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
Cerevance today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).
News Archive
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
Cerevance to deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated gene, leading to progressive neurological issues. Using Cerevance’s NETSseq platform, RNA from purified cerebellar cell types of A-T and control donors was analyzed and subsequently revealed significant astrocyte gene expression changes related to inflammation and immune response.
July 10, 2023
Alzheimers Association International Conference
June 28, 2023
XVI European Meeting on Glial Cells in Health and Disease
June 26, 2023
Gordon Research Conference
Events Archive
October 21, 2024
CVN424, a GPR6 Inverse Agonist, for Parkinson’s Disease and Motor Fluctuations: A Double-Blind, Randomized, Phase 2 Trial
June 30, 2021
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
April 5, 2024
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment
February 15, 2023
Characterisation of C101248: A Novel Selective THIK-1 Channel Inhibitor for the Modulation of Microglial NLRP3-Inflammasome
Ossola, B., Rifat, A., Rowland, A., Hunter, H., Drinkall, S., Bender, C., Hamlischer, M., Teall, M., Burley, R., Barke, D., Cadwalladr, D., Dickson, L., Lawrence, J., Harvey, J., Lizio, M., Xu, X., Kavanagh, E., Cheung, T., Sheardown, S., Lawrence, C.B., Harte, M., Brough, D., Madry, C., Matthews, K., Doyle, K., Page, K., Powell, J., Brice, N.L., Bürli, R.W., Carlton, M.B., Dawson L.A.
Viewview